SAN DIEGO, CA, April 6 /PRNewswire-FirstCall/ - Stressgen Biotechnologies Corporation ("Stressgen") announced that effective today, Robert Rieder, Vice Chairman and Chief Executive Officer of Cardiome Pharma Corp., has joined the Board of Directors. In addition, Jay M. Short, Ph.D. has been appointed Chairman of the Board replacing R. Ian Lennox who announced his resignation from the Board.
"We are extremely pleased with Bob Rieder's appointment to our Board of Directors," commented Gregory M. McKee, President and Chief Executive Officer. "We believe his extensive experience in the healthcare industry and exemplary track record building Cardiome Pharma make him an ideal addition to our Board. We are also pleased that Jay Short has agreed to serve as Chairman, providing continued scientific and business leadership. We would like to take this opportunity to sincerely thank Ian Lennox for his dedicated service and significant contribution to the Company."
Mr. Rieder joined Cardiome in April of 1988 as President and Chief Executive Officer, and was recently appointed as the Company's Vice Chairman of the Board. Mr. Rieder has extensive experience in venture capital and in operational management. Prior to joining Cardiome, he was Vice President at MDS Ventures Pacific Inc., the Vancouver-based affiliate of MDS Capital Corp., and has served as a director for nine public and private technology companies. In his venture capital career, Mr. Rieder led several rounds of financing for Stressgen and was a director of the Company from 1992 until 2000. Prior to joining MDS, Mr. Rieder was President and Chief Executive Officer of Synapse Technologies and Chief Operating Officer of DBA Telecom Inc. Mr. Rieder received his BASc (Chem. Eng.) from the University of British Columbia and his MBA from the University of Western Ontario.
Dr. Short has served on the Stressgen Board of Directors for twelve years. In 2005, Dr. Short became Chairman, President and Founder of the E. O. Wilson Biodiversity Foundation in San Diego, California. Dr. Short served as President, Chief Executive Officer, Chief Technology Officer, Director and Founder of Diversa Corporation from September 1994 to October 2005.
About Stressgen Biotechnologies Corporation:
Stressgen is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol SSB. For more information about Stressgen, please visit the website located at www.stressgen.com.
Director, Investor Relations
6055 Lusk Boulevard
San Diego, CA USA 92121
Stressgen Biotechnologies Corp.
CONTACT: Stressgen: Donna Slade, Director, Investor Relations, 6055 LuskBoulevard, San Diego, CA, USA 92121, Tel: (858) 202-4900, Dir: (858)202-4945, Fax: (858) 450-6849, firstname.lastname@example.org